Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic

Molecular Neurobiology

Volumn 53, Issue 4, 2016, Pages 2189-2199

  Schmitz, Matthias ^a   Ebert, Elisabeth ^a   Stoeck, Katharina ^a   Karch, André ^a   Collins, Steven ^b   Calero, Miguel ^c   Sklaviadis, Theodor ^d   Laplanche, Jean Louis ^e   Golanska, Ewa ^f   Baldeiras, Ines ^g   Satoh, Katsuya ^h   Sanchez Valle, Raquel ⁱ   Ladogana, Anna ^j   Skinningsrud, Anders ^k   Hammarin, Anna Lena ^l   Mitrova, Eva ^m   Llorens, Franc ^a   Kim, Yong Sun ⁿ   Green, Alison ^o   Zerr, Inga ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e HÔPITAL LARIBOISIÈRE   (France)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g UNIVERSITY OF COIMBRA   (Portugal)

^h NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^k Department of Multidisiplinary Laboratory Medicine and Medical Biochemistry Division of Diagnostics and Technology Akerhus University Hospital 1478 Lørenskog ^*  (Norway)

^l SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^m SLOVAK MEDICAL UNIVERSITY   (Slovakia)

ⁿ Hallym University   (South Korea)

^o WESTERN GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

14 3 3 protein; Biomarker; Cerebrospinal fluid; Creutzfeldt Jakob disease; Pre mortem test; Standardization

Indexed keywords

PROTEIN 14 3 3; BIOLOGICAL MARKER; ISOPROTEIN; PROTEIN S 100; TAU PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CONTAMINATION; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FEMALE; FREEZING; GERMANY; HEMOLYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN STABILITY; RELIABILITY; REPRODUCIBILITY; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; STORAGE TEMPERATURE; THAWING; VALIDATION STUDY; WESTERN BLOTTING; CEREBROSPINAL FLUID; CREUTZFELDT-JAKOB SYNDROME; LABORATORY; METABOLISM; PRESERVATION; STANDARD;

14-3-3 PROTEINS; BIOMARKERS; BLOTTING, WESTERN; CREUTZFELDT-JAKOB SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LABORATORIES; PRESERVATION, BIOLOGICAL; PROTEIN ISOFORMS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84928958024     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9167-5     Document Type: Article

References (43)

1. Broadie K, Rushton E, Skoulakis E, Davis R (1997) Leonardo, a Drosophila 14-3-3 protein involved in learning, regulates presynaptic function. Neuron 2:391–402
2. van Hemert M, Steensma H, van Heusden G (2001) 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays 10:936–946
3. Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, Windl O, Kretzschmar HA, Weber T (1998) Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 43:32–40
4. Zerr I, Bodemer M, Weber T (1997) The 14-3-3 brain protein and transmissible spongiform encephalopathy [letter]. N Engl J Med 336:874
5. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro CJ, Knight RSG, Bernheimer H, Cardone F, Delasnerie-Lauprêtre N, Cuadrado Corrales N, Ladogana A, Fletcher A, Bodemer M, Awan T, Ruiz Bremón A, Budka H, Laplanche JL, Will RG, Poser S (2000) Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 55:811–815
6. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie DA, Smith P, Varges D, Heinemann U, Meissner B, Roberts H, Brandel JP, Van Dujin CM, Pocchiari M, Begue P, Cras P, Will RG, Sanchez-Juan P (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 132:2659–2668
7. Gmitterová K, Heinemann U, Bodemer M, Krasnianski A, Meissner B, Kretzschmar HA, Zerr I (2008) 14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes. Neurobiol Aging 30:842–850
8. WHO (1998) Human transmissible spongiform encephalopathies. Wkly Epidemiol Rec 47:361–365
9. Schmitz M, Lüllmann K, Zafar S, Ebert E, Wohlhage M, Oikonomou P, Schlomm M, Mitrova E, Beekes M, Zerr I (2014) Association of prion protein genotype and scrapie prion protein type with cellular prion protein charge isoform profiles in cerebrospinal fluid of humans with sporadic of familial prion diseases. Neurobiol Aging 35:1177–1188
10. Schmitz M, Schlomm M, Hasan B, Beekes M, Mitrova E, Korth C, Brell A, Carimalo J, Gawinecka J, Varges D, Zerr I (2010) Codon 129 polymorphism and the E200K mutation do not affect the cellular prion protein isoform composition in the cerebrospinal fluid from patients with Creutzfeldt-Jakob disease. Eur J Neurosci 31:2024–2031
11. Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P (2012) Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol 11:618–628
12. Stoeck K, Sanchez-Juan P, Gawinecka J, Green A, Ladogana A, Pocchiari M, Sanchez-Valle R, Mitrova E, Sklaviadis T, Kulczycki J, Slivarichova D, Saiz A, Calero M, Knight R, Aguzzi A, Laplanche JL, Peoc’h K, Schelzke G, Karch A, van Duijn CM, Zerr I (2012) Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain 135:3051–3061
13. Beaudry P, Cohen P, Brandel JP, Delasnerie-Laupretre N, Richard S, Launay JM, Laplanche JL (1999) 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 10:40–46
14. Geschwind M, Martindale J, Miller D, De Armond SJ, Uyehara-Lock J, Gaskin D, Kramer JH, Barbaro NM, Miller BL (2003) Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 60:813–816
15. Cuadrado-Corrales N, Jiménez-Huete A, Albo C, Hortiguela R, Vega L, Cerrato L, Sierra-Moros M, Rábano A, de Pedro-Cuesta J, Calero M (2006) Impact of the clinical context on the 14-3-3 test for the diagnosis of sporadic CJD. BMC Neurol 6:25
16. Green AJ (2002) Use of 14-3-3 in the diagnosis of Creutzfeldt-Jakob disease. Biochem Soc Symp 30:382–386
17. Green AJ, Thompson EJ, Stewart GE, Zeidler M, McKenzie JM, MacLeod M-A, Ironside JW, Will RG, Knight RS (2001) Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 70:744–748
18. Zerr I, Bodemer M, Räcker S, Grosche S, Poser S, Kretzschmar HA, Weber T (1995) Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 345:1609–1610
19. Zerr I, Bodemer M, Westermann R, Schröter A, Jacobi C, Arlt S, Otto M, Poser S (2000) 14-3-3 proteins in neurological disorders. J Neurol 247(Suppl 3):III/14
20. Matsui Y, Satoh K, Miyazaki T, Shirabe S, Atarashi R, Mutsukura K, Satoh A, Kataoka Y, Nishida N (2011) High sensitivity of an ELISA kit for dedection of the gamma-isoform of 14-3-3 proteins: usefulness in laboratory diagnosis of human prion disease. BMC Neurol 11, doi:10.1186/471-2377-11-120
21. Atarashi R, Sano K,Fuse T, Yamaguchi N, Ishibashi D, Matsubara T, Nakagaki T, Yamanaka H, Shirabe S, Yamada M, Mizusawa H, Kitamoto T, Klug G, McGlade A, Collins SJ, Nishida N (2011) Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion.Nat Med 17:175–178
22. Cramm M, Schmitz M, Karch A, Zafar S, Varges D, Mitrova E, Schroeder B, Raeber AJ, Kuhn F, Zerr I (2015) Characteristic CSF prion-seeding efficiency in humans with prion diseases. Mol Neurobiol 51:396–405
23. Cramm M, Schmitz M, Zafar S, Karch A, Mitrova E, Schroeder B, Raeber A, Kuhn F, Satoh K, Collins S, Zerr I (2015) Stability and reproducibility underscore utility of RT-QuIC CSF analysis for diagnosis of human prion disease, in press
24. McGuire LI, Peden AH, Orrú CD, Wilham JM, Appleford NE, Mallinson G, Andrews M, Head MW, Caughey B, Will RG, Knight RS, Green AJ (2012) Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol 72:278–285
25. Sano K, Satoh K, Atarashi R, Takashima H, Iwasaki Y, Yoshida M, Sanjo N, Murai H, Mizusawa H, Schmitz M, Zerr I, Kim YS, Nishida N (2013) Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay. PLoS ONE 8:e54915
26. Coulthart MB, Jansen GH, Olsen E, Godal DL, Connolly T, Choi BC, Wang Z, Cashman NR (2011) Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study. BMC Neurol 11:133
27. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sanchez-Valle R, Mitrova E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichova D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens C, Van Duijn C, Zerr I (2006) CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 67:637–643
28. Ramont L, Thoannes H, Volondat A, Chastang F, Millet MC, Maquart FX (2005) Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. Clin Chem Lab Med 43:1215–1217
29. Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, Näslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L (2000) Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med 6:291–302
30. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, Scheltens P, Blankenstein MA (2005) Effects of processing and storage conditions on amyloid beta (1–42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 51:189–195
31. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of beta-amyloid (1–42) in cerebrospinal fluid and plasma. Amyloid 7:245–258
32. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, Cras P (1993) Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitisve sandwich enzyme-linked immunosorbent assay. J Neurochem 61:1828–1834
33. Hsich G, Kenney K, Gibbs CJ Jr, Lee KH, Harrington MG (1996) The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongifrom encephalopathies. N Engl J Med 335:924–930
34. Lemstra AW, van Meegen MT, Vreyling JP, Meijerink PH, Jansen GH, Bulk S, Baas F, van Gool WA (2000) 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients. Neurology 55:514–516
35. Kenney K, Brechtel C, Takahashi H, Kurohara K, Anderson P, Gibbs CJ Jr (2000) An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann Neurol 48:395–398
36. Collins S, Boyd A, Fletcher A, Gonzales M, McLean CA, Byron K, Masters CL (2000) Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid. J Clin Neurosci 7:203–208
37. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P (2003) A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 74:1210–1214
38. Castellani RJ, Colucci M, Xie Z, Zou W, Li C, Parchi P, Capellari S, Pastore M, Rahbar MH, Chen SG, Gambetti P (2004) Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology 63:436–442
39. Collins SJ, Sanchez-Juan P, Masters CL, Klug GM, van Duijn C, Poleggi A, Pocchiari M, Almonti S, Cuadrado-Corrales N, de Pedro-Cuesta J, Budka H, Gelpi E, Glatzel M, Tolnay M, Hewer E, Zerr I, Heinemann U, Kretzschmar HA, Jansen GH, Olsen E, Mitrova E, Alpérovitsch A, Brandel JP, Mackenzie J, Murray K, Will RG (2006) Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 129:2278–2287
40. Baldeiras IE, Ribeiro MH, Pacheco P, Machado A, Santana I, Cunha L, Oliveira C (2009) Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients. J Neurol 256:1540–1550
41. Begué P, Martinetto H, Schultz M, Rojas E, Romero C, D’Giano C, Sevlever G, Somoza M, Taratuto A (2011) Creutzfeldt-Jakob disease surveillance in Argentina, 1997–2008. Neuroepidemiology 37:193–202
42. Hamlin C, Puoti G, Berri S, Sting E, Harris C, Cohen M, Spear C, Bizzi A, Debanne SM, Rowland DY (2012) A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology 79:547–552
43. Chohan G, Pennington C, Mackenzie J, Andrews M, Everington D, Will R, Knight R, Green A (2010) The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry 81:1243–1248